X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
LP-100 in combination with PARP inhibitors preferentially damages DNA in cancer cells lacking nucleotide excision repair capabilities. Sensitivity to LP-100 is also higher in tumors with HRR deficiency, which involved in the repair of DNA damage from LP-100.
Lead Product(s): Irofulven,Olaparib
Therapeutic Area: Oncology Product Name: LP-100
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 09, 2023
Details:
The research collaboration will focus on further validating findings from RADR® regarding the effectiveness of Lantern's LP-184 and LP-284 in genomically-defined pediatric cancers, including several without any effective therapeutic approach.
Lead Product(s): Irofulven
Therapeutic Area: Oncology Product Name: LP-184
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: The Greehey Children's Cancer Research Institute
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 15, 2022
Details:
Rare pediatric disease designation and Orphan drug designation received from FDA based on both the in-silico and in-vivo observations, LP-184 has the potential to become a critical part of the armamentarium of approved treatment for ATRT.
Lead Product(s): Irofulven
Therapeutic Area: Oncology Product Name: LP-184
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 24, 2022
Details:
This collaboration, together with the growing power of the RADR® platform, can potentially uncover new drug combinations using LP-100 and LP-184 for cancer treatments at a fraction of the cost of traditional drug development.
Lead Product(s): Irofulven
Therapeutic Area: Oncology Product Name: LP-100
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: The Danish Cancer Society Research Center
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 18, 2022
Details:
The expansion of this collaboration comes after identifying several gene signatures that predict a potential response of a patient's tumor to Lantern's drug candidates, LP-184 and LP-284.
Lead Product(s): Irofulven
Therapeutic Area: Oncology Product Name: LP-184
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Cancer Institute
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Expanded Collaboration January 12, 2022
Details:
LP-184, a PTGR1-activated small molecule that leverages DNA repair deficiency to selectively eradicate pancreatic cancers, and potential clinical uses of LP-184 in an upcoming Phase I clinical trial.
Lead Product(s): Irofulven
Therapeutic Area: Oncology Product Name: LP-184
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 12, 2021
Details:
LP-184 is a small molecule drug candidate and next generation alkylating agent that preferentially damages DNA in cancer cells that over-express certain biomarkers or that harbor mutations in DNA repair pathways.
Lead Product(s): Irofulven
Therapeutic Area: Oncology Product Name: LP-184
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 11, 2021
Details:
Irofulven is a well-studied small molecule that causes bulky single strand DNA adducts that cause DNA damage in cancer cells, which can only be repaired by the transcription coupled nucleotide excision repair (TC-NER) pathway.
Lead Product(s): Irofulven
Therapeutic Area: Oncology Product Name: LP-100
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Lantern Pharma
Deal Size: $18.0 million Upfront Cash: Undisclosed
Deal Type: Agreement July 26, 2021
Details:
The collaboration focuses Lantern's drug candidate LP-184 in the area of brain tumors, and specifically in Atypical Teratoid Rhabdoid Tumors ("ATRT"), an ultra-rare and fast-growing cancerous tumor of the brain that presents primarily in children.
Lead Product(s): Irofulven
Therapeutic Area: Oncology Product Name: LP-184
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Lantern Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 01, 2021
Details:
The collaboration focuses on a larger set of PDX models and help pinpoint the specific mechanism of action, and seek confirmatory validation of the role of PTGR1 and the genetic mutations driving the DNA damage repair pathways that make LP-184 highly potent in Prostate Cancer.
Lead Product(s): Irofulven
Therapeutic Area: Oncology Product Name: LP-184
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Lantern Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 05, 2020
Details:
The Fox Chase collaboration will focus on advancing the targeted use of LP-184 in molecularly-defined sub-types of pancreatic cancer.
Lead Product(s): Irofulven
Therapeutic Area: Oncology Product Name: LP-184
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Lantern Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 22, 2020
Details:
Each presentation will examine Lantern Pharma’s use of its A.I. platform, RADR® (Response Algorithm for Drug Positioning and Rescue), in the development of LP-184, one of three cancer drugs in Lantern Pharma’s pipeline.
Lead Product(s): Irofulven
Therapeutic Area: Oncology Product Name: LP-184
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 17, 2020
Details:
Funds is directed towards Lantern Pharma's most advanced candidate is LP-100, a potential treatment for prostate cancer that is in a Phase 2 trial with out-licensing partner Oncology Venture.
Lead Product(s): Irofulven
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $29.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering April 16, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
